<DOC>
	<DOCNO>NCT01474122</DOCNO>
	<brief_summary>The DUAL-2 study design multicenter , double-blind two-period study initial fix 16-week Period 1 , follow Period 2 variable duration . All patient complete Period 1 continue original randomized treatment Period 2 , last randomized patient complete Period 1 . Patients randomize 1:1:1 ratio ( macitentan 3mg : macitentan 10mg : placebo ) . The primary objective demonstrate effect macitentan reduction number new digital ulcer patient systemic sclerosis ongoing digital ulcer ( DU ) . Other objective include : - evaluation efficacy macitentan hand functionality DU burden Week 16 SSc patient ongoing DU disease . - evaluation safety tolerability macitentan patient . - evaluation efficacy macitentan time first DU complication entire treatment period .</brief_summary>
	<brief_title>Macitentan Treatment Digital Ulcers Systemic Sclerosis Patients</brief_title>
	<detailed_description>Recurrent digital ulcer ( DU ) manifestation vascular disease patient systemic sclerosis ( SSc ) , important source morbidity lead impaired function patient . In study , investigate whether treatment endothelin receptor antagonist , macitentan , decrease development new digital ulcer patient SSc . Macitentan highly potent , tissue-targeting dual endothelin receptor antagonist . Through complete blockade endothelin action , macitentan expect protect tissue damage effect elevate endothelin . This therapy approve treatment systemic sclerosis , use ERA attractive approach combat structural vascular damage observe SSc lead complication DUs .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Inclusion Criteria : Patients â‰¥ 18 year age Women childbearing potential must use two reliable method contraception Diagnosis SSc accord classification criterion American College Rheumatology ( ACR ) At least one visible , active ischemic DU baseline History least one additional recent active ischemic digital ulcer Exclusion Criteria : DUs due condition SSc Symptomatic pulmonary arterial hypertension ( PAH ) Body mass index ( BMI ) &lt; 18 kg/m^2 Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 1.5 x upper limit normal ( ULN ) Hemoglobin &lt; 75 % low limit normal range Systolic blood pressure &lt; 95 mmHg diastolic blood pressure &lt; 50 mmHg Severe malabsorption ; severe organ failure ( e.g. , lung , kidney ) , lifethreatening condition Females pregnant breastfeeding plan course study Substance alcohol abuse dependence , tobacco use level Treatment phosphodiesterase5 ( PDE5 ) inhibitor Patients statin , receive treatment le 3 month prior Screening whose treatment stable period Patients vasodilator , receive treatment le 2 week prior Screening whose treatment stable period Treatment prostanoids within 3 month Treatment disease modify agent present less 3 month prior Screening whose treatment stable least 1 month prior Screening Treatment oral corticosteroid ( &gt; 10 mg/day prednisone equivalent ) . Treatment endothelin receptor antagonist ( ERAs ) within 3 month Systemic antibiotic treat infect DU ( ) within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>digital ulcer</keyword>
	<keyword>systemic sclerosis</keyword>
</DOC>